Wave Life Sciences Ltd.
WVE
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company aā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$5.74
Price+4.18%
$0.23
1Y
Price
Market Cap
$1.131b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-3134.7%
EBITDA Margin-3052.6%
Net Profit Margin-2166.4%
Free Cash Flow Margin-3134.7%
EBITDA Margin-3052.6%
Net Profit Margin-2166.4%
Free Cash Flow MarginRevenue
$65.371m
+53.0%
1y CAGR-4.0%
3y CAGR+748.3%
5y CAGREarnings
-$202.473m
+0.9%
1y CAGR-59.5%
3y CAGR-28.5%
5y CAGREPS
-$1.09
+9.9%
1y CAGR-30.9%
3y CAGR-4.7%
5y CAGRBook Value
$453.520m
$558.321m
Assets$104.801m
Liabilities$43.590m
DebtDebt to Assets
7.8%
-0.2x
Debt to EBITDAFree Cash Flow
-$186.239m
+0.7%
1y CAGR-220.8%
3y CAGR-144.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company